Cargando…
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option
Classic hairy cell leukemia (HCL) is a rare indolent B‑cell-lymphoproliferative disorder, first described as a distinct disease entity in 1958. After more than two decades without effective chemotherapeutic options and a dismal prognosis of less than 5 years, only the introduction of interferon‑α (I...
Autores principales: | Bohn, Jan-Paul, Gastl, Guenther, Steurer, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923076/ https://www.ncbi.nlm.nih.gov/pubmed/27429657 http://dx.doi.org/10.1007/s12254-016-0269-1 |
Ejemplares similares
-
Low‐dose vemurafenib in hairy cell leukemia patients with active infection
por: Bohn, Jan‐Paul, et al.
Publicado: (2019) -
Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant
por: Liu, Qiuying, et al.
Publicado: (2021) -
The Biology of Classic Hairy Cell Leukemia
por: Bohn, Jan-Paul, et al.
Publicado: (2021) -
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia‐variant
por: Locher, Maurus, et al.
Publicado: (2020) -
Current and emerging treatment options for hairy cell leukemia
por: López-Rubio, Montserrat, et al.
Publicado: (2015)